Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit Review(S)-Crizotinib
说明： MTH1 inhibitor
化学名： 3-[(1S)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-2-pyridinamine
纯度： ≥98% (HPLC)
生物活性 for (S)-Crizotinib
(S)-Crizotinib is a potent MTH1 inhibitor (IC50 = 72 nM). Induces DNA damage and disrupts nucleotide pool homeostasis in cancer cells. Also attenuates colony formation of KRAS-mutated PANC1 cells in vitro. Suppresses tumor growth ~50% in a colon cancer carcinoma xenograft model.
许可信息
Sold for research purposes under agreement from Pfizer Inc
化合物库 for (S)-Crizotinib
(S)-Crizotinib is also offered as part of the Tocriscreen 2.0 Max. 了解 Tocris 化合物库的更多信息。
技术数据 for (S)-Crizotinib
| 分子量 | 450.34 |
| 公式 | C21H22Cl2FN5O |
| 储存 | Store at RT |
| 纯度 | ≥98% (HPLC) |
| CAS Number | 1374356-45-2 |
| PubChem ID | 56671814 |
| InChI Key | KTEIFNKAUNYNJU-LBPRGKRZSA-N |
| Smiles | C[C@@H](C1=C(C(F)=CC=C1Cl)Cl)OC2=CC(C3=CN(C4CCNCC4)N=C3)=CN=C2N |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶解性数据 for (S)-Crizotinib
| 溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
|---|---|---|---|
| 溶解性 | |||
| DMSO | 22.52 | 50 | |
| 1eq. HCl | 9.01 | 20 温和加热 |
制备储备液 for (S)-Crizotinib
以下数据基于产品分子量 450.34。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| 浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.5 mM | 4.44 mL | 22.21 mL | 44.41 mL |
| 2.5 mM | 0.89 mL | 4.44 mL | 8.88 mL |
| 5 mM | 0.44 mL | 2.22 mL | 4.44 mL |
| 25 mM | 0.09 mL | 0.44 mL | 0.89 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
产品说明书 for (S)-Crizotinib
参考文献 for (S)-Crizotinib
参考文献是支持产品生物活性的出版物。
Huber et al (2014) Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy. Nature 508 222 PMID: 24695225
If you know of a relevant reference for (S)-Crizotinib, please let us know.
按标靶查看相关产品
按产品操作查看相关产品
关键词: (S)-Crizotinib, (S)-Crizotinib supplier, potent, MTH1, inhibitors, inhibits, ras, transformation, anticancer, hydrolases, g, proteins, mutT, homologue, NUDT1, nucleotide, pool, homeostasis, DNA, damage, MutT, homolog-1, (MTH1), 6025, Tocris Bioscience
1 篇 (S)-Crizotinib 的引用文献
引用文献是使用了 Tocris 产品的出版物。 (S)-Crizotinib 的部分引用包括：
Noemi et al (2020) The Epstein-Barr virus nuclear antigen-1 upregulates the cellular antioxidant defense to enable B-cell growth transformation and immortalization. Oncogene 39 603-616 PMID: 31511648
您是否知道使用了 Tocris (S)-Crizotinib 的优秀论文？ 请告知我们.
(S)-Crizotinib 的评论
目前没有该产品的评论。 Be the first to review (S)-Crizotinib and earn rewards!
Have you used (S)-Crizotinib?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Cancer Metabolism Research Product Guide
This product guide reviews some of the main areas in cancer metabolism research and lists around 150 products that can be used to investigate metabolic pathways in cancer including:
- Glycolysis
- Tricarboxylic Acid Cycle
- Lipidogenesis
- 1C Metabolism and Nucleic Acid Synthesis
- Drivers of Metabolic Reprogramming
- pH and Redox Balance
Cancer Metabolism Poster
This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.
Epigenetics in Cancer Poster
This poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.